Author's response to reviews
|
|
- Beatrice Jackson
- 6 years ago
- Views:
Transcription
1 Author's response to reviews Authors: Marit Synnestvedt Elin Borgen Erik Wist Gro Wiedswang Kjetil Weyde Terje Risberg Christian Kersten Ingvil Mjaaland Lise Vindi Cecilie Schirmer Jahn Martin Nesland Bjørn Naume Version: 3 Date: 5 November 2012 Author's response to reviews: see over
2 Version: 1 Reviewer number: 1 This is a very interesting study on the use of bone marrow DTCs as a tool to select patients for secondary adjuvant treatment strategies in early breast cancer. The authors provide data only about the detection of DTCs since the follow-up data are not yet mature. Major Strengths: 1. The authors have performed bone marrow biopsies in a prospective series of more than 1000 patients with early breast cancer at two time points (3 and 9 months after treatment). These data provide important information about the fate of DTCs and the reproducibility of the DTC detection overtime. Moreover, the have used DTC detection as a tool to decide for a secondary adjuvant treatment strategy and have monitor DTCs after docetaxel treatment. The authors should be praised for using this novel treatment approach. 2. The authors have detected DTCs following appropriate methodology based on international guidelines. Major weaknesses: 1. The authors come to a conclusion that is not fully supported by their data. Since they did not use a randomization design, they cannot state in the abstract conclusion that After docetaxel rescue treatment, the majority of patients experience disappearance of the DTCs. Instead, they should mention that since this is not a randomized trial, the observed results could be either due to limitations of the detection technology for DTCs or due to the effect of concomitant trastuzumab or endocrine treatment or due to docetaxel itself. This statement in the conclusion of the abstract is now modified in line with reviewer # 1 comments (page 5). Among the 72 BM2-positive, docetaxel-treated patients, 15 (20.8%) had persistent DTCs at BM3 and 4. The same or even higher conversion rate was observed in patients not receiving docetaxel. Indeed, among the 94 BM1 positive patients, only 15 (16%) had persistent DTCs at BM2 without receiving any docetaxel treatment. What was the effect of endocrine treatment or trastuzumab in these BM1-positive patients? Have any of these patients received
3 bisphosphonates that have been shown to affect DTC detection? The authors need to provide specific information about the administration of endocrine treatment and/or trastuzumab and/or bisphosphonates between BM1 and BM2 but also between BM2 and BM3 or BM4. The authors need to provide a supplementary table with complete DTC status at all timepoints for BM1-positive patients. For each BM1-positive patient, they need to provide information about the administration or not of endocrine treatment and /or trastuzumab and/or bisphosphonates. Similarly, in sup table 2 for each BM2 positive patient, they need to provide information about the administration or not of endocrine treatment and /or trastuzumab and/or bisphosphonates. The change in BM status between BM1 and BM2 can be affected by the recent administration of the standard adjuvant chemotherapy (this was the rationale for using the BM2 time point for selection of patients to docetaxel treatment, as described in the introduction). A change from BM1 positive to BM2 negative DTC-status was observed in 82.4% (61/74) of the endocrine treated patients, in 87.5% (7/8) of the trastuzumab treated patients (4 of the patients were treated with both endocrine therapy and trastuzumab) and in 85.7%(6/7) of the patients that did not receive endocrine treatment or trastuzumab. This point and these results have now been included in the Result section (page 12) According to reviewer # 1 comments, we have provided a supplementary table with information about the administration of endocrine treatment and/or trastuzumab in addition to information about complete BM status for each BM1 positive patient and/or BM2 positive patient (also see the Results section, page 13). None of the patients in the study received bisphosphonates. We have also added a section in Methods (in the Patients section, page 8) for further clarification of the adjuvant treatment given in this study, 2. They authors need to discuss other randomized trials of bisphosphonate administration and DTC detection such as the studies by Aft et al Lancet Oncology 2010 and Solomayer et al Annals of Oncology We agree that the discussion about bisphosphonate administration and DTC detection is an important point. We have added a section about this issue in the Discussion (page 17). Minor comment: The authors need to update ref 21 and 22. The references have been updated (Reference list, ref 17 and 18 in reviced reference list).
4 Version: 2 Reviewer number: 2 This manuscript presents descriptive data on 1121 patients with pn1-3 or pt1c/t2g2-3pn0 breast cancer. Bone marrow-aspiration was performed 8-12 weeks after chemotherapy (bone marrow1), followed by a second bone marrow-aspiration 6 months later (bone marrow2). DTC-status was determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells, which can be considered as gold standard. The prevalence of positive bone marrow status and its correlation to tumor characteristics is presented. Major comments: This manuscript focuses on a clinical interesting topic with lack of data: the fate of disseminated tumor cells after primary systemic treatment and its relevance for further clinical management The main weakness of this manuscript is that no follow-up data is being presented We have not presented clinical follow-up data, because we are not allowed to perform survival analyses vs BM results before the last follow-up has been completed in the study and the clinical follow-up data have been finally monitored. This is in accordance with the apriori statistical considerations for the study. The follow-up is still ongoing. This has been clarified in the Methods (page 9), and also mentioned in the Introduction (Background) (page 7) and Discussion (page 18). We still feel that the descriptive results from the study is of importance, because there is great need for tools to monitor the effect of adjuvant treatment in order to test alternative treatment approaches for patients that are insufficiently treated. This novel approach gives information that can be helpful for the scientific community in preparing studies addressing this topic. Also, our study compares DTC results with clinicopathological parameters that gives clinically relevant information, which we feel support the publication of our results so far. The second major weakness of this study is that no randomization for pts with positive BM2 was performed, i.e. that all these pts received docetaxel. This study design will not lead to meaningful results on the benefit of treatment after positive BM2 We are aware of the weakness of the lack of randomization in the present study and we have already discussed this issue in a section in the Discussion of the manuscript.
5 Whether the study design will lead to meaningful treatment-related results, in our opinion, is dependent upon the final clinical data. But this study also presents a principle for monitoring of treatment, which is supported by a recent randomized study by Solomayer et al (Annals of Oncology 2012). Introduction: the first paragraph is general knowledge and little enlightening in the context of this study The introduction in general is lengthy and should be more concise We have shortened the Introduction (Background) to make it more concise, including removal of most of the first paragraph. Methods: recruitment ended in 2008: why are there no FU-data being presented? We have not presented clinical follow-up data, because we are not allowed to perform survival analyses vs BM results before the last follow-up has been completed in the study and the clinical follow-up data have been finally monitored. This is in accordance with the statistical considerations described for the study. The follow-up is still ongoing. Discussion: the above mentioned weaknesses are no addressed adequately in the discussion, i.e. phrasing clearly suggest a true change in the tumor cell load after the intervention is by far too speculative We have modified the text in the Discussion in accordance with the reviewer # 2 comments (page 14). Minor comments: docetaxel rescue treatment: this terminology is not correct in primary treatment We have removed the term rescue in the text in the Conclusion section in the Abstract (page 5) and in Conclusions (page 19). Table 3: percentages should be presented We have added precentages in Table 3.
6 Version: 2 Reviewer number: 3 The manuscript by Sennestvedt et al reports the results of bone marrow disseminated tumor cells detection at several time points after the primary treatment of localized brest cancer. This study included non-randomized administration of a second adjuvant chemotherapy in patients who had DTC after the end of anthracycline-baseed chemotherapy. This is a prospective study, headed by a recognized research team focused on DTC & CTC, and the patient compliance is astonishing. The final survival results are not disclosed in this report but the changes in BM DTC detection are interesting, supporting the use of a second adjuvant chemotherapy in BM DTC+ patients. The article is clear and well written, the discussion adresses the main issues of this study. So, I recommend this article for publication without any major changes. small things to be fixed: Reference #35 : "Alix" instead of "ix" Reference #36 has no clear interest & can be removed Reference #43 may be replaced by Vincent-Salomon & al Br J Cancer 2007 (FISH being more relevant than immunocytostaining for HER2). All these points have been corrected.
7 Version: 2 Reviewer number: 4 The authors are presenting interesting data on disseminated tumor cells as a surrogate of minimal residual disease. The disappearance of DTCs after docetaxel-rescue-treatment one year after diagnosis shows that DTCs are indeed not a phenomenon of the primary tumor but play an important role in breast cancer as a systemic disease. This offers the possibility to monitor effectivity of adjuvant treatment and to offer non-responders extended adjuvant therapy. I am excited about the follow-up data to prove the clinical importance of these observations.
Title: Persistent tumor cells in bone marrow of early breast cancer patients after primary surgery are associated with inferior outcome
Author's response to reviews Title: Persistent tumor cells in bone marrow of early breast cancer patients after primary surgery are associated with inferior outcome Authors: Kjersti Tjensvoll (ktje@sus.no)
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationTitle: A Prospective Study of Dietary Selenium Intake and Risk of Type 2 Diabetes
Author's response to reviews Title: A Prospective Study of Dietary Selenium Intake and Risk of Type 2 Diabetes Authors: Saverio Stranges (S.Stranges@warwick.ac.uk) Sabina Sieri (Sabina.Sieri@istitutotumori.mi.it)
More informationGuideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies
1 2 3 26 July 2018 EMA/CHMP/459559/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the use of minimal residual disease as a clinical endpoint in multiple Draft Draft agreed
More informationCover Letter. Reviewer 1:
Cover Letter Michael Yang, M.D., Ph.D. Managing Editor of Cancer Research Frontiers 1188 Willis Ave, #109, Albertson, NY 11507, USA Phone: +1-917-426-1571 http://cancer-research-frontiers.org/ Dear Dr.
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationSurvey Results Q1. How would you best describe your organization?
Survey Results Q1. How would you best describe your organization? Q2. How high would you rate the priority of Circulating Tumor Cells in you organization? Q3. What do you think is the biggest challenge
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationEarly dissemination in prostate cancer
Early dissemination in prostate cancer Miodrag Guzvic, University of Regensburg, Germany Adjuvant Palliative M0 Initiation Diagnosis Surgery Metastasis Death Intervention window to delay or prevent metastasis
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationThe Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer
Welcome! The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer Prof. Sabine Kasimir-Bauer Department of Gynecology and Obstetrics University Hospital
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationFor the Reviewer # 1 For specific requested changes to the manuscript (point-by-point response):
Author s response to reviews Title: Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: A case report Authors: Choukri Elm'hadi (dr.choukrielmhadi@hotmail.com)
More informationEuropean Commission Initiative on Breast Cancer (ECIBC) MEETING OF MONITORING SUBGROUP Ispra, 14 September 2016 (10:00-17:00) Minutes
EUROPEAN COMMISSION DIRECTORATE GENERAL JOINT RESEARCH CENTRE Directorate F Health, Consumers and Reference Materials Unit F1 Health in Society European Commission Initiative on Breast Cancer (ECIBC) MEETING
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationA Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
The new england journal of medicine original article A Pooled Analysis of Bone Marrow in Breast Cancer Stephan Braun, M.D., Florian D. Vogl, M.D., Bjørn Naume, M.D., Wolfgang Janni, M.D., Michael P. Osborne,
More informationPhiladelphia College of Osteopathic Medicine. Dara Colasurdo Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Does The Use Of Intravenous Zoledronic
More informationAuthor s response to reviews
Author s response to reviews Title: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1 or -2 mutated Her2
More informationRe: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationAuthor's response to reviews
Author's response to reviews Title: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis Authors:
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationFollow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care
Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationStatistical validation of biomarkers and surogate endpoints
Statistical validation of biomarkers and surogate endpoints Marc Buyse, ScD IDDI, Louvain-la-Neuve & Hasselt University, Belgium marc.buyse@iddi.com OUTLINE 1. Setting the scene: definitions and types
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More information1. Introduction. Correspondence should be addressed to François-Clément Bidard; Received 28 March 2013; Accepted 19 April 2013
International Breast Cancer Volume 203, Article ID 30470, 5 pages http://dx.doi.org/0.55/203/30470 Clinical Study Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic
More informationJanet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario
Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design
More informationBasis for Conclusions: ISA 230 (Redrafted), Audit Documentation
Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation Prepared by the Staff of the International Auditing and Assurance Standards Board December 2007 , AUDIT DOCUMENTATION This Basis for Conclusions
More informationCancer Chemotherapy in Clinical Practice
Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Terry Priestman Terry Priestman, MD, FRCP, FRCR New Cross Hospital Wolverhampton UK British Library Cataloguing in Publication
More informationAuthor's response to reviews
Author's response to reviews Authors: Rohini Sharma (r.sharma@imperial.ac.uk) David C Cunningham (David.Cunningham@rmh.nhs.uk) Paul Smith (p.smith@ctc.ucl.ac.uk) Graham R Robertson (grobertson@med.usyd.edu.au)
More informationSequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells
Original article Annals of Oncology 13: 1044 1048, 2002 DOI: 10.1093/annonc/mdf184 Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationAuthor's response to reviews
Author's response to reviews Title: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon the cost-effectiveness of lapatinib plus letrozole and discussed the challenges of using letrozole alone as a comparator and/or using trastuzumab plus anastrozole as a comparator.
More informationOVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF MIGRAINE
European Medicines Agency London, 24 January 2007 Doc. Ref. EMEA/CHMP/EWP/21477/2007 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF
More informationAneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline
Breast Cancer and Pregnancy Guideline N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed versions of the document. The Intranet should be referred
More informationTitle: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
Author's response to reviews Title: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Authors: Sven Mahner (Sven.Mahner@gmx.de) Linn Woelber (lwoelber@uke.uni-hamburg.de)
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationPrognostic and Predictive Factors
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Prognostic and Predictive Factors Prognostic and Predictive Factors Version 2002: Thomssen / Harbeck Version 2003 2009: Costa
More informationLiquid Biopsy: Implications for Cancer Staging & Therapy
Prof. Klaus Pantel, MD, PhD Institut für Tumorbiologie Liquid Biopsy: Implications for Cancer Staging & Therapy Tumor cell dissemination and cancer dormancy Primary tumor Local relapse Cancer cells disseminate
More informationADAPT. Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
ADAPT Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer Therapieindikation gesteuert durch prognostische Information
More informationInformation for Patients. Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Information for Patients Guidance on the use of trastuzumab for the treatment of advanced breast cancer March 2002 This leaflet is also available in Welsh, (Ref no. N0067). Mae'r daflen hon hefyd ar gael
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationBlood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation
More informationDeveloping language writing convincingly (Example from undergraduate Cultural Studies)
Developing language writing convincingly (Example from undergraduate Cultural Studies) Read the paragraph below and consider the following questions: Which sentences are presented as fact and which as
More informationTitle: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives
Author s response to reviews Title: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives Authors: Robert Beckett (rdbeckett@manchester.edu) Kathryn
More informationTitle: Effects of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients - a one-year follow up
Author s response to reviews Title: Effects of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients - a one-year follow up Authors: Ana Isabel Penzlin (ana.penzlin@ppcr.org)
More informationPEER REVIEW HISTORY ARTICLE DETAILS. Zou, Yuming; Li, Quan; Xu, Weidong VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationSUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE
SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE COMMENTS FROM Astellas Pharma Europe BV, Elisabethhof 19, 2353EW Leiderdorp, The Netherlands GENERAL COMMENTS A guiding document on the
More informationAuthor s response to reviews. Title: Attitudes towards assisted dying are influenced by question wording and order: a survey experiment.
Author s response to reviews Title: Attitudes towards assisted dying are influenced by question wording and order: a survey experiment Authors: Morten Magelssen (magelssen@gmail.com) Magne Supphellen (Magne.Supphellen@nhh.no)
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationSentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy
ONCOLOGY REPORTS 15: 927-931, 2005 927 Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy YOSUKE TANAKA 1, HIRONORI MAEDA 2, YASUHIRO OGAWA 3, AKIHITO NISHIOKA 3, SATOSHI
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationStopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?
Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data? Pinuccia Valagussa Fondazione Michelangelo, Milano I have no relevant relationships to disclose
More informationSupplementary Online Content
Supplementary Online Content Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. doi:10.1001/jama.2016.21038 Additional
More informationConflict of interest in randomised controlled surgical trials: Systematic review, qualitative and quantitative analysis
Reviewer Assessment Open Access P. Probst, K. Grummich, U. Klaiber, P. Knebel, A.Ulrich, M. W. Büchler, and M. K. Diener* Conflict of interest in randomised controlled surgical trials: Systematic review,
More informationJules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President
Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Ball State University
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationCurrent Status and Future Development of Tools for Prognosis and Prediction - USA
Current Status and Future Development of Tools for Prognosis and Prediction - USA John H. Ward, MD Professor of Medicine University of Utah School of Medicine Huntsman Cancer Institute October18, 2009
More informationCTC molecular characterization: Are we ready to move forward with clinical testing?
CTC molecular characterization: Are we ready to move forward with clinical testing? Michail Ignatiadis MD, PhD Jules Bordet Institute, Université Libre de Bruxelles Brussels, Belgium Breast cancer: Diagnostics
More informationTitle:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis
Author's response to reviews Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis Authors: Mihai Strachinaru (m.strachinaru@erasmusmc.nl) Bas
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationRESPONSE TO DECISION LETTER
RESPONSE TO DECISION LETTER Dear Editor-in-chief, We are grateful to the editors and reviewers for their time and constructive comments on our manuscript. We have implemented their comments and suggestions
More informationReview Article Circulating Tumor Cells in Breast Cancer Patients: An Evolving Role in Patient Prognosis and Disease Progression
SAGE-Hindawi Access to Research Pathology Research International Volume 2011, Article ID 621090, 7 pages doi:10.4061/2011/621090 Review Article Circulating Tumor Cells in Breast Cancer Patients: An Evolving
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationThe DATECAN initiative
The DATECAN initiative Definition and Assessment of Time-to-event Endpoints in CANcer trials Carine BELLERA INSERM U1219 et Institut Bergonié, Bordeaux On behalf of the DATECAN steering committee Genesis
More informationTitle:Systematic review and meta-analysis of the effect of increased vegetable and fruit consumption on body weight and energy intake
Author's response to reviews Title:Systematic review and meta-analysis of the effect of increased vegetable and fruit consumption on body weight and energy intake Authors: Oliver T Mytton (otm21@medschl.cam.ac.uk)
More informationPaper No. 9 (IPR ) Entered: January 23, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
Trials@uspto.gov Paper No. 7 (IPR2017-01726) 571-272-7822 Paper No. 9 (IPR2017-01727) Entered: January 23, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD PFIZER,
More informationReport to the editors of the journal
Report to the editors of the journal I would first like to thank you, madam / sir, for this collaboration with our journal Interventions économiques / Papers in Political Economy. Those invited to do a
More informationTitle: Socioeconomic conditions and number of pain sites in women
Author's response to reviews Title: Socioeconomic conditions and number of pain sites in women Authors: Finn E Skjeldestad (fisk@fhi.no) Toril Rannestad (Toril.Rannestad@hist.no) Version: 2 Date: 17 January
More informationAuthor s response to reviews
Author s response to reviews Title: Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT)) - Study protocol for a national, multicentre
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationTitle: Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study
Author's response to reviews Title: Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study Authors: Øystein Riise (oystein.riise@rikshospitalet.no)
More informationFramework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Framework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM) MRD in Multiple Myeloma Team Biomarker Qualification Workshop Framework
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationAuthor's response to reviews
Author's response to reviews Title: Physiotherapy interventions in scientific physiotherapy publications focusing on interventions for children with cerebral palsy: A qualitative phenomenographic approach.
More informationAuthor's response to reviews
Author's response to reviews Title: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus
More informationOverview of comments received on the draft 'Information in the package leaflet for aspartame' (EMA/CHMP/134648/2015)
9 October 2017 EMA/CHMP/581993/2016 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on the draft 'Information in the package leaflet for aspartame' (EMA/CHMP/134648/2015)
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More information논문투고및투고후소통하기 : 영문교정작업, 실제논문투고하기, revision 답변달기, query form 작성하기
Apr 28, 2018 9:20-9:40 JGO Workshop 논문투고및투고후소통하기 : 영문교정작업, 실제논문투고하기, revision 답변달기, query form 작성하기 연세의대이정윤 좋은아이디어를얻기위하여, 타인으로부터유익한암시를받을때가있음. 새로운아이디어는두사람이상의지식및아이디어를함께모을때생겨나는경우가있음. 토론은잘못의발견에유익한방법임. 혼자독립하여동료와이야기를나누지않는연구자는틀린길을걸어가다많은시간을낭비하게되는경우가있음.
More informationBone Marrow Synoptic Reporting for Hematologic Neoplasms
Bone Marrow Synoptic Reporting for Hematologic Neoplasms Guideline from the College of American Pathologists (CAP) Pathology and Laboratory Quality Center Publication: March 1, 2016 Archives of Pathology
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval DRAFT GUIDANCE This guidance document
More information